US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARIA Opportunities ETF

26.04

-0.1520-0.58%

Post-market: 25.97-0.0713-0.27%19:30 EDT

Volume:379

Turnover:9.88K

Market Cap:12.58M

PE:- -

High:26.04

Open:25.97

Low:25.97

Close:26.19

52wk High:26.76

52wk Low:24.54

Shares:483.20K

Float Shares:483.20K

Volume Ratio:3.37

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

Braiin Unveils AI Agent for Property Sector, Shares Soar Over 60%

Braiin Launches Agentic AI Workforce ARIA to Capture the US$32.0 Billion Global Real Estate Software Market by 2033

Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Alpha Modus Introduces ARIA: Enterprise AI for Physical Retail, Built on Anthropic's Claude and Backed by 12 Granted U.S. Patents

PAIR and Cambridge NeuroWorks launch new online neuroscience seminar series in May 2026

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ARIA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIA Opportunities ETF","latestPrice":26.0413,"timestamp":1791403200000,"preClose":26.1933,"halted":0,"volume":379,"hourTrading":{"tag":"盘后","latestPrice":25.97,"preClose":26.0413,"latestTime":"19:30 EDT","volume":6,"amount":156.2478,"timestamp":1791415806169,"change":-0.0713,"changeRate":-0.002738,"amplitude":0},"delay":0,"changeRate":-0.00580301069357435,"floatShares":483200,"shares":483200,"eps":0,"marketStatus":"Not Yet Opened","change":-0.152,"latestTime":"10-07 16:00:00 EDT","open":25.97,"high":26.0413,"low":25.97,"amount":9881.071212,"amplitude":0.002722,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791446400000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":26.1933,"nav":26.2,"aum":12661191.1,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.97,"preClose":26.0413,"latestTime":"19:30 EDT","volume":6,"amount":156.2478,"timestamp":1791415806169,"change":-0.0713,"changeRate":-0.002738,"amplitude":0},"volumeRatio":3.371888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":483200,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.371888,"shares":483200,"dividePrice":0,"high":26.0413,"amplitude":0.002722,"preClose":26.1933,"low":25.97,"week52Low":24.5362,"pbRate":"--","week52High":26.7557,"institutionHeld":0.5771,"latestPrice":26.0413,"eps":0,"divideRate":0,"volume":379,"delay":0,"ttmEps":0,"open":25.97,"prevYearClose":24.76,"prevWeekClose":25.8906,"prevMonthClose":25.5521,"prevQuarterClose":25.5521,"fiveDayClose":25.5521,"twentyDayClose":25.6357},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARIA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661327966","title":"LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2661327966","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661327966?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:04","pubTimestamp":1787573040,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.)TOKYO and CAMBRIDGE, Mass., Aug.  24, 2026 (GLOBE N","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349698/0/en/leqembi-iqlik-lecanemab-irmb-autoinjector-for-initiation-of-therapy-now-available-in-the-u-s-for-early-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA","CAA","AD","BK4080","BK4132","CDR","MCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654236190","title":"ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2654236190","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654236190?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:00","pubTimestamp":1785182400,"startTime":"0","endTime":"0","summary":"Cambridge, Massachusetts, July  27, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333844/0/en/ProMIS-Neurosciences-to-Host-Webinar-to-Discuss-Upcoming-6-Month-Blinded-Interim-Data-from-PRECISE-AD-Phase-1b-Trial-of-PMN310-in-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0757428866.USD","HST","ARIA","BK4023","LU1815336091.USD","LU2125909759.SGD","LU1169590202.USD","LU0053671581.USD","LU2125909916.SGD","BK4218","BK4143","BK4585","BK4132","LU1169589451.USD","BK4181","LU1923622291.USD","AD","LU0154245756.USD","LU2211815571.USD","MSA","LU0154245673.USD","PD","LU0728928796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651142696","title":"FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2651142696","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651142696?lang=en_us&edition=fundamental","pubTime":"2026-07-14 05:38","pubTimestamp":1783978680,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosingfor initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326503/0/en/FDA-Approves-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-as-an-Initiation-Dose-for-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA","AD","CDR","BK4588","BK4132","BK4080","MCI","CAA","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199098091","title":"Braiin Unveils AI Agent for Property Sector, Shares Soar Over 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199098091","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199098091?lang=en_us&edition=fundamental","pubTime":"2026-07-14 03:00","pubTimestamp":1783969238,"startTime":"0","endTime":"0","summary":"Braiin Limited announced the launch of its new AI agent, ARIA, on Monday, marking its official entry into the property technology sector. The company's stock surged as much as 62% following the news,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09979","159819","BK1148","REET","ARIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651114331","title":"Braiin Launches Agentic AI Workforce ARIA to Capture the US$32.0 Billion Global Real Estate Software Market by 2033","url":"https://stock-news.laohu8.com/highlight/detail?id=2651114331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651114331?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:30","pubTimestamp":1783945800,"startTime":"0","endTime":"0","summary":"ARIA brings agentic AI execution to property management, leasing, compliance, accounting support, and customer engagement MELBOURNE, Australia, July  13, 2026  (GLOBE NEWSWIRE) -- Braiin Limited (“Bra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326186/0/en/Braiin-Launches-Agentic-AI-Workforce-ARIA-to-Capture-the-US-32-0-Billion-Global-Real-Estate-Software-Market-by-2033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AIPO","QTOC","VTHR","REET","BK4588","BRAI","BK4023","ARTY","QQH","ARIA","CHAT","VGT","AGIX","IGM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650974350","title":"Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier","url":"https://stock-news.laohu8.com/highlight/detail?id=2650974350","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650974350?lang=en_us&edition=fundamental","pubTime":"2026-07-10 04:01","pubTimestamp":1783627260,"startTime":"0","endTime":"0","summary":"Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent scientific advances and future opportunities t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/09/3325186/0/en/Denali-Therapeutics-to-Give-Opening-Plenary-Address-at-Alzheimer-s-Association-International-Conference-AAIC-2026-and-Highlight-Breakthroughs-in-Delivering-Biologic-Therapies-Acros.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","TV","CTA","ARIA","BK4007","BK4139","ATV","BBB","ETV","BK4100","AAIC","BK4115","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638654500","title":"Alpha Modus Introduces ARIA: Enterprise AI for Physical Retail, Built on Anthropic's Claude and Backed by 12 Granted U.S. Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2638654500","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638654500?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:13","pubTimestamp":1779883980,"startTime":"0","endTime":"0","summary":"Alpha Modus's patent retail technology AI portfolio has a platform. ARIA, the Adaptive Retail Intelligence Architecture, is purpose-built on Anthropic's Claude and is moving toward commercializationCO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301926/0/en/Alpha-Modus-Introduces-ARIA-Enterprise-AI-for-Physical-Retail-Built-on-Anthropic-s-Claude-and-Backed-by-12-Granted-U-S-Patents.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","ARIA","BK4023","AMOD","AI","BK4588","BK4585","AIPO","BK4528","BK4543","AGIX","VGT","AIYY","ARTY","BK4587","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636023325","title":"PAIR and Cambridge NeuroWorks launch new online neuroscience seminar series in May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636023325","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636023325?lang=en_us&edition=fundamental","pubTime":"2026-05-18 16:00","pubTimestamp":1779091200,"startTime":"0","endTime":"0","summary":"HONG KONG, May 18, 2026 /PRNewswire/ -- The PolyU Academy for Interdisciplinary Research  of The Hong Kong Polytechnic University has joined forces withCambridge NeuroWorks, UK, made up of nine partners including the University of Cambridge, to launch a new online seminar series in neuroscience. The inaugural seminar, delivered by Prof. Edward CHANG of the University of California, is being held on 27 May 2026.This strategic partnership brings together institutions with complementary strengths. PAIR is recognised for advancing interdisciplinary research across brain health, biomedical engineering, data science and healthcare innovation, with a strong focus on real-world impact. Cambridge NeuroWorks is a transformative neurotechnology initiative led and hosted by Cambridge University Health Partners  and powered by the Advanced Research and Invention Agency , the UK's R&D funding agency created to unlock scientific and technological breakthroughs that benefit everyone. It aims to build ","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2981965/20260527_Cambridge_NeuroWorks_Joint_Seminar_Series__1200_x_627_px.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2981965/20260527_Cambridge_NeuroWorks_Joint_Seminar_Series__1200_x_627_px.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pair-and-cambridge-neuroworks-launch-new-online-neuroscience-seminar-series-in-may-2026-302774467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633482746","title":"Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2633482746","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633482746?lang=en_us&edition=fundamental","pubTime":"2026-05-08 14:30","pubTimestamp":1778221800,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., May  08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3290827/0/en/Update-on-FDA-Priority-Review-of-LEQEMBI-IQLIK-lecanemab-irmb-Subcutaneous-Injection-as-a-Starting-Dose-for-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAA","LABU","BK4588","AD","MCI","ARIA","BK4585","BK4132"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}